SCHEMBL3784975

SCHEMBL3784975

CCOCCCn1ncc2ccc(I)cc21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.41
CHRM1 P11229 2/20 0.41
KMO O15229 6/20 0.40
HTR2A P28223 5/20 0.40
HTR2C P28335 5/20 0.40
HTR2B P41595 4/20 0.40
HTR1A P08908 2/20 0.35
ADRA2A P08913 2/20 0.35
ADRA2B P18089 2/20 0.35
ADRA2C P18825 2/20 0.35
HTR1D P28221 1/20 0.35
HTR7 P34969 1/20 0.35
HTR4 Q13639 1/20 0.35
REN P00797 2/20 0.34
BRD4 O60885 2/20 0.33
NOTUM Q6P988 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4D Q08499 1/20 0.33
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3779615 0.86 KMO (0.42) CHRM2CHRM1KMOHTR2AHTR2C
SCHEMBL3777872 0.83 HTR2A (0.40) CHRM2CHRM1KMOHTR2AHTR2C
SCHEMBL6741175 0.81 HTR2A (0.46) KMOHTR2AHTR2CHTR2BHTR1A
SCHEMBL29351604 0.80 CYP1A2 (0.51) CHRM2CHRM1KMOCYP1A2
Ammonia Solution, Strong SCHEMBL8009916 0.80 HTR2A (0.45) KMOHTR2AHTR2CHTR2BHTR1A
SCHEMBL8007547 0.79 HTR2A (0.55) KMOHTR2AHTR2CHTR2BHTR1A
SCHEMBL3784965 0.73 HTR2A (0.42) CHRM2CHRM1KMOHTR2AHTR2C
SCHEMBL14908760 0.73 HTR2A (0.43) CHRM2CHRM1KMOHTR2AHTR2C
SCHEMBL30855572 0.73 HTR2A (0.36) KMOHTR2AHTR2CHTR2BHTR1A
SCHEMBL2144622 0.73 HTR2A (0.36) KMOHTR2AHTR2CHTR2BHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084485-B2 6-(aminoalkyl)indazoles VITAE PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-20100331287-A1 6-(Aminoalkyl)Indazoles VITAE PHARMACEUTICALS, INC. 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331287-A1 6-(Aminoalkyl)Indazoles REN, AGTR1, AGTR2 CHRM2 2716/4885CHRM1 2803/4885KMO 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.